illumi
gene® Mycoplasma Direct – Targeted diagnosis from day one of symptoms.

- **Sensitivity** — Direct molecular detection of up to 4X more positives than serology

- **Speed** — Precise results in less than one hour

- **Simplicity** — Minimal technical expertise required

- **Affordable** — No capital investment necessary

**SEROLOGY MAY ONLY DETECT 25% OF POSITIVES IN THE FIRST WEEK.**

*WHEN SEROLOGY MISSES *MYCOPLASMA PNEUMONIAE*, IT’S TIME TO CHANGE THE WAY YOU TEST*
ACCURATE
• Direct detection of *Mycoplasma pneumoniae* infections
• Improved test performance over traditional methods
• Single target test for increased clinical performance

FAST & STREAMLINED
• Simple sample preparation from throat swabs
• Less than 2 minutes of hands-on time & 40 minutes amplification time
• Eliminate the need for repeat patient visits

EFFICIENT & COMPACT DESIGN
• Small footprint, easily adaptable to laboratory needs
• Ready to use reagents
• Kit storage at room temperature

AFFORDABLE TECHNOLOGY
• No capital investment necessary
• No annual maintenance charges
• Training and implementation at no extra charge

### REFERENCES
1. illumiGene® Mycoplasma Direct Package Insert, SN11194.

For more information in the US, contact a specialist at 1-888-763-6769.

### WORLD HEADQUARTERS
3471 River Hills Drive, Cincinnati, Ohio 45244 | Tel.: 1-513-271-3700
E-mail: mbi@meridianbioscience.com

**illumiGene**


### CLINICAL PERFORMANCE
- **POSITIVE AGREEMENT**: 96.0%
- **NEGATIVE AGREEMENT**: 97.7%
- **OVERALL AGREEMENT**: 97.6%
- **INVALID RATE**: 0.0%

Catalogue No. 280250

**OTHER illumiGene® TESTS AVAILABLE:**
- *C. difficile*
- *Chlamydia (CT) [Export Only]*
- *Gonorrhea (NG) [Export Only]*
- *Group A Streptococcus*
- *Group B Streptococcus*
- *HSV 1&2*
- *Malaria [Export Only]*
- *Mycoplasma*
- *Pertussis*

*Not cleared for use in the United States.*